Sylvia E. Schwarz
Affimed Therapeutics (Germany)(DE)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Fungal and yeast genetics research, Cancer-related Molecular Pathways
Most-Cited Works
- → Role of Predicted Metalloprotease Motif of Jab1/Csn5 in Cleavage of Nedd8 from Cul1(2002)693 cited
- → Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1(1999)509 cited
- → The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme(1998)212 cited
- → Characterization of Human hect Domain Family Members and Their Interaction with UbcH5 and UbcH7(1998)174 cited
- → Cloning of Human Ubiquitin-conjugating Enzymes UbcH6 and UbcH7 (E2-F1) and Characterization of Their Interaction with E6-AP and RSP5(1996)153 cited
- → A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma(2020)149 cited
- → The ubiquitin‐protein ligase E6‐associated protein (E6‐AP) serves as its own substrate(1998)128 cited
- → The nucleotide sequence of Saccharomyces cerevisiae chromosome IV(1997)80 cited
- → A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data(2018)16 cited
- → INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE(2019)10 cited